228 related articles for article (PubMed ID: 34468906)
21. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.
Borghorst S; Hempel G; Poppenborg S; Franke D; König T; Baumgart J
Cancer Chemother Pharmacol; 2014 Aug; 74(2):367-78. PubMed ID: 24934864
[TBL] [Abstract][Full Text] [Related]
23. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
24. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.
Asselin BL
Adv Exp Med Biol; 1999; 457():621-9. PubMed ID: 10500842
[TBL] [Abstract][Full Text] [Related]
25. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
27. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
[TBL] [Abstract][Full Text] [Related]
28. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
29. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
Fernandez CA; Stewart E; Panetta JC; Wilkinson MR; Morrison AR; Finkelman FD; Sandlund JT; Pui CH; Jeha S; Relling MV; Campbell PK
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1307-13. PubMed ID: 24771103
[TBL] [Abstract][Full Text] [Related]
30. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
Gervais D; Corn T; Downer A; Smith S; Jennings A
AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
[TBL] [Abstract][Full Text] [Related]
31. Production of a novel N-terminal PEGylated crisantaspase.
Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
Vieira Pinheiro JP; Ahlke E; Nowak-Göttl U; Hempel G; Müller HJ; Lümkemann K; Schrappe M; Rath B; Fleischhack G; Mann G; Boos J
Br J Haematol; 1999 Feb; 104(2):313-20. PubMed ID: 10050714
[TBL] [Abstract][Full Text] [Related]
33. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
34. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
35. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
[TBL] [Abstract][Full Text] [Related]
36. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.
Egler RA; Ahuja SP; Matloub Y
J Pharmacol Pharmacother; 2016; 7(2):62-71. PubMed ID: 27440950
[TBL] [Abstract][Full Text] [Related]
37. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
38. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
39. L-asparaginase from
Saeed H; Elsawy E; Shalaby M; Abdel-Fattah M; Hemida A; Eldoksh A; Ataya FS; Nematalla H; Elkewedi M; Labrou NN; El-Nikhely N
Prep Biochem Biotechnol; 2022; 52(6):668-680. PubMed ID: 34612174
[TBL] [Abstract][Full Text] [Related]
40. Comparative pharmacokinetic studies of three asparaginase preparations.
Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]